Blueprint Medicines Corp (BPMC) Receives Average Rating of “Buy” from Analysts
Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have been assigned a consensus rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $98.67.
A number of research analysts have issued reports on BPMC shares. BidaskClub cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, August 1st. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Guggenheim started coverage on shares of Blueprint Medicines in a report on Tuesday, September 18th. They issued a “buy” rating and a $102.00 target price for the company. Finally, Leerink Swann started coverage on shares of Blueprint Medicines in a report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 target price for the company.
In other news, insider Marion Dorsch sold 2,300 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $70.47, for a total value of $162,081.00. Following the sale, the insider now directly owns 2,300 shares in the company, valued at $162,081. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares in the company, valued at $1,269,800. The disclosure for this sale can be found here. 3.15% of the stock is owned by corporate insiders.
Blueprint Medicines stock traded up $0.58 during mid-day trading on Thursday, reaching $60.36. The company had a trading volume of 346,198 shares, compared to its average volume of 426,459. Blueprint Medicines has a 1 year low of $57.31 and a 1 year high of $109.00. The company has a current ratio of 10.05, a quick ratio of 10.05 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.64 billion, a PE ratio of -15.40 and a beta of 1.46.
Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.87 million. During the same period last year, the business posted ($0.96) earnings per share. The company’s quarterly revenue was down 86.4% on a year-over-year basis. On average, sell-side analysts forecast that Blueprint Medicines will post -5.25 EPS for the current fiscal year.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.